There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Siragusa, S. (2008). Low molecular weight heparins as antineoplastic agents. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 3, 159-161 [10.2174/157489208783478676].
Low molecular weight heparins as antineoplastic agents.
SIRAGUSA, Sergio
2008-01-01
Abstract
There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
| File | Dimensione | Formato | |
|---|---|---|---|
|
PRA-3-3-Siragusa.pdf
Solo gestori archvio
Descrizione: rec pat anticancer drug
Dimensione
37.35 kB
Formato
Adobe PDF
|
37.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
